All In Biotech

Drug Trial Radar · NCT01831427

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 (Andecaliximab) in Adults With Moderate to Severe Active Ulcerative Colitis

A Phase 1 Double-blind, Randomized, Placebo-Controlled, Staggered, Single and Multiple Ascending Dose, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of GS-5745 in Subjects With Moderate to Severe Ulcerative Colitis

Last checked: Nov 20, 2026Latest source record: Feb 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

74

Actual

Start

Mar 28, 2013

Primary completion

Jan 5, 2015

Study completion Feb 6, 2015

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Apr 15, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objectives of this study are as follows: * To assess the safety and tolerability of escalating single and multiple doses of GS-5745 (andecaliximab) in participants with moderate to severe ulcerative colitis (UC) as assessed by adverse events (AEs) and laboratory abnormalities * To assess the pharmacokinetics (PK) of GS-5745 (andecaliximab) in participants with moderate to severe UC.

Conditions

  • Ulcerative Colitis

Interventions

  • AndecaliximabDrug

    Andecaliximab administered by intravenous (IV) infusion or subcutaneous (SC) injection

  • Placebo to match AndecaliximabDrug

    Placebo to match andecaliximab administered by IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Experienced Any Treatment-Emergent Adverse Events (TEAEs) (SAD/MAD)Time frame: SAD Cohorts: First dose date (Day 1) plus 30 days, MAD/Adaptive MAD Cohort: First dose date up to last dose date (Maximum: Day 29) plus 30 days
  2. Pharmacokinetic (PK) Parameter: Cmax (SAD)Time frame: Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43
  3. PK Parameter: Cmax (MAD)Time frame: MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Days 1 and 29, Predose on Days 8 and 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Days 1, and 29, Predose on Days 8 and 36
  4. PK Parameter: Ctau (MAD)Time frame: MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Day 29; Predose on Day 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Day 29; Predose on Day 36
  5. PK Parameter: AUCinf (SAD)Time frame: Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43
  6. PK Parameter: AUCtau (MAD)Time frame: MAD Cohorts: Predose and 1, 2, and 6 hours postdose on Days 1 and 29; Predose on Days 8 and 36; Adaptive MAD Cohort: Predose and 6 hours postdose on Days 1, and 29; Predose on Days 8 and 36
  7. PK Parameter: AUClast (SAD)Time frame: Predose and 1, 2, and 6 hours postdose on Day 1; Days 2, 3, 8, 15, 29, and 43

Locations

16 sites in 7 countries. Site status is shown where the registry gives one.

  • Delta Research Partners LLC

    Monroe, Louisiana

  • Walter Reed National Military Medical Center

    Bethesda, Maryland

  • Clinical Research Institute of Michigan

    Chesterfield Township, MI 48047, Michigan

  • Ehrhardt Clinical Research, LLC

    Belton, Missouri

  • Duke University Medical Center

    Durham, North Carolina

  • Community Research

    Cincinnati, Ohio

  • UZ Leuven

    Leuven, Belgium

  • GIRI

    Vancouver, British Columbia, Canada

  • LHSC University Campus

    London, Ontario, Canada

  • Drug Research Centre

    Balatonfüred, Hungary

  • Clinical Pharma Center of Kenezy Gyula Korhaz Rendelointezet

    Debrecen, Hajdú-Bihar, Hungary

  • Semmelweis Egyetem Altalanos Orvostudomanyi Kar

    Budapest, Pest County, Hungary

  • Republican Clinical Hospital

    Chisinau, Moldova

  • Academic Medical Center

    Amsterdam, Netherlands

  • Academisch Ziekenhuis Maastricht

    Maastricht, Netherlands

  • Institute of Pulmonology "Marius Nasta"

    Bucharest, Romania

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.